Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Question

<< Previous

Bullboard Posts

Next >>

Comment by scarlet1967on Jun 23, 2021 9:25am

107 Views

Post# 33433518

RE:RE:RE:Question

"They beat the Gothenburg guys".

Below is their patent coverage, the Swedish researchers need to find out how to target the sortilin overexpression not infringing THTX’s with great global coverage and solid patent.

“In another aspect, there is provided a method of treating a cancer involving sortilin expression comprising contacting at least one cancer cell expressing sortilin with at least one compound as defined herein.”

https://patents.google.com/patent/WO2017088058A1/en

Wino115 wrote:
That was a question in the KOL event and Marsolais emphatically stated their peptide does not cross BBB and Beliveau nodded along with him.

My recollection from reading some of the original Katana and Angiochem material was that the labs initial focus was finding a way to cross the BBB and designing drugs for that purpose. That is what Angiochem is doing. same team also discovered this peptide that latched to sort1. It didn't work for brain tumors, but they saw it could work for other solid tumors with high Sort1 and spun the tech out as Katana. When they were pitching it around the whole science behind sort1 was still very early. You can see from the dates of Beliveau articles on the website that it was truly groundbreaking science UQAM did. They beat the Gothenburg guys by years.I'm sure one of the reasons Katana took a year or more to find a partner was that it was so early and very little clinical work had been done around that idea. It fit well with an equally smallish company able to put $10mil down to see if it could advance in the lab. Kudos to THTX mgmt for taking that risk.

qwerty22 wrote:

Sortilin is best known as a brain protein, it's expressed on the surface of neurons. I would think one of the first things you look at is does it cross the BBB. If Katana/thtx haven't ticked this off the to do list early in the process then we are invested in fools. Could they have not done this? Are they all fools?

SABBOBCAT wrote: Wasn't Katana working on peptides to cross the blood bran barrier before selling the platform to TH? Is there any risk that the PDC would cross the BBB and have into tended side effects?